Search results
Approach: Activation of fetal hemoglobin. BEAM-101 is an investigational therapy that produces base edits designed to potentially alleviate the effects of sickle cell disease by mimicking genetic variants seen in individuals who have hereditary persistence of fetal hemoglobin.
- About Us | Beam Therapeutics
Dr. Giuseppe Ciaramella is the President of Beam...
- Our Science | Beam Therapeutics
In 2017, Beam Therapeutics was founded by gene editing...
- Beam Therapeutics Announces Pipeline and Business Highlights ...
CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Beam...
- Beam Therapeutics Reports Pipeline and Business Highlights ...
Building on its acquisition of Guide Therapeutics, Beam is...
- About Us | Beam Therapeutics
People also ask
What did Beam Therapeutics report in Q2 2023?
What did Beam Therapeutics do in 2022?
Who is Beam Therapeutics?
Does Lilly buy Beam & Verve Therapeutics?
Nov 8, 2023 · Recent Portfolio Prioritization Focuses Business on Key Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline. Lilly Acquires Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Cardiovascular Programs for up to $600 Million in Combined Upfront Payment, Equity Investment and Potential Future Development ...
Aug 9, 2022 · CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today provided pipeline and business updates and reported financial results for the second quarter ended June 30, 2022.
Feb 28, 2022 · Building on its acquisition of Guide Therapeutics, Beam is using a DNA-barcoded LNP screening technology to enable high-throughput in vivo identification of LNPs with novel biodistribution and selectivity for target organs beyond the liver.
Nov 8, 2023 · CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported...
May 7, 2024 · CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported...
Aug 8, 2023 · CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported...
